Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Improving Diversity of Dental Students Through the Boston University Master's of Oral Health Sciences Postbaccalaureate Program.

Davies TA, Kaye E, Stahlberger M, Abbas M, Sarkis C, Reed L, Dunham L, Schreiber BM, Leone C, Mascarenhas AK.

J Dent Educ. 2019 Mar;83(3):287-295. doi: 10.21815/JDE.019.024. Epub 2019 Jan 28.

PMID:
30692183
2.

Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated Escherichia coli Vaccine.

Abbanat D, Davies TA, Amsler K, He W, Fae K, Janssen S, Poolman JT, van den Dobbelsteen GPJM.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00123-17. doi: 10.1128/CVI.00123-17. Print 2017 Dec.

3.

Interactive Cognitive-Motor Step Training Improves Cognitive Risk Factors of Falling in Older Adults - A Randomized Controlled Trial.

Schoene D, Valenzuela T, Toson B, Delbaere K, Severino C, Garcia J, Davies TA, Russell F, Smith ST, Lord SR.

PLoS One. 2015 Dec 16;10(12):e0145161. doi: 10.1371/journal.pone.0145161. eCollection 2015.

4.
5.

Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries.

Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN.

J Antimicrob Chemother. 2014 Jul;69(7):1804-14. doi: 10.1093/jac/dku048. Epub 2014 Mar 5.

PMID:
24603963
6.

A Stroop Stepping Test (SST) using low-cost computer game technology discriminates between older fallers and non-fallers.

Schoene D, Smith ST, Davies TA, Delbaere K, Lord SR.

Age Ageing. 2014 Mar;43(2):285-9. doi: 10.1093/ageing/aft157. Epub 2013 Oct 14.

PMID:
24128593
7.

Step Training System: an ICT solution to measure and reduce fall risk in older adults.

Smith ST, Davies TA, Lennox J.

Conf Proc IEEE Eng Med Biol Soc. 2013;2013:7033-5. doi: 10.1109/EMBC.2013.6611177.

PMID:
24111364
8.

IMP-33, a New IMP variant detected in Pseudomonas aeruginosa from Sicily.

Deshpande LM, Davies TA, Blandino G, Nicoletti G, Jones RN, Castanheira M.

Antimicrob Agents Chemother. 2013 Dec;57(12):6401-3. doi: 10.1128/AAC.02532-12. Epub 2013 Sep 16. No abstract available.

9.

Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.

Queenan AM, Davies TA, He W, Lynch AS.

J Chemother. 2013 Jun;25(3):141-7. doi: 10.1179/1973947813Y.0000000074.

PMID:
23783138
10.

A randomized controlled pilot study of home-based step training in older people using videogame technology.

Schoene D, Lord SR, Delbaere K, Severino C, Davies TA, Smith ST.

PLoS One. 2013;8(3):e57734. doi: 10.1371/journal.pone.0057734. Epub 2013 Mar 5.

11.

Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program.

Morrow BJ, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA.

Diagn Microbiol Infect Dis. 2013 Apr;75(4):412-6. doi: 10.1016/j.diagmicrobio.2012.12.012. Epub 2013 Feb 5.

PMID:
23391609
12.

In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.

He W, Kaniga K, Lynch AS, Flamm RK, Davies TA.

Diagn Microbiol Infect Dis. 2012 Dec;74(4):417-9. doi: 10.1016/j.diagmicrobio.2012.08.014. Epub 2012 Sep 17.

PMID:
22995366
13.

Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010.

Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA.

Diagn Microbiol Infect Dis. 2012 Jul;73(3):267-70. doi: 10.1016/j.diagmicrobio.2012.04.002. Epub 2012 May 12.

PMID:
22579652
14.

Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone.

Davies TA, Flamm RK, Lynch AS.

Int J Antimicrob Agents. 2012 Jun;39(6):534-8. doi: 10.1016/j.ijantimicag.2012.02.016. Epub 2012 Apr 21.

PMID:
22526015
15.

Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.

Morrow BJ, Abbanat D, Baum EZ, Crespo-Carbone SM, Davies TA, He W, Shang W, Queenan AM, Lynch AS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21. doi: 10.1128/AAC.00470-11. Epub 2011 Sep 12.

16.

Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.

Davies TA, Marie Queenan A, Morrow BJ, Shang W, Amsler K, He W, Lynch AS, Pillar C, Flamm RK.

J Antimicrob Chemother. 2011 Oct;66(10):2298-307. doi: 10.1093/jac/dkr290. Epub 2011 Jul 20.

PMID:
21775338
17.

Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.

Davies TA, He W, Bush K, Flamm RK.

Antimicrob Agents Chemother. 2010 Oct;54(10):4510-2. doi: 10.1128/AAC.00590-10. Epub 2010 Aug 9.

18.

Effects of ceftobiprole and oxacillin on mecA expression in methicillin-resistant Staphylococcus aureus clinical isolates.

Shang W, Davies TA, Flamm RK, Bush K.

Antimicrob Agents Chemother. 2010 Feb;54(2):956-9. doi: 10.1128/AAC.01024-09. Epub 2009 Nov 30.

19.

Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.

Baum EZ, Crespo-Carbone SM, Morrow BJ, Davies TA, Foleno BD, He W, Queenan AM, Bush K.

Antimicrob Agents Chemother. 2009 Jul;53(7):2785-90. doi: 10.1128/AAC.00018-09. Epub 2009 May 11.

20.

Molecular characterisation of meticillin-resistant Staphylococcus aureus isolates from two ceftobiprole Phase 3 complicated skin and skin-structure infection clinical trials.

Davies TA, Shang W, Amsler KM, Bajaksouzian S, Jacobs MR, Bush K.

Int J Antimicrob Agents. 2009 Aug;34(2):166-8. doi: 10.1016/j.ijantimicag.2009.02.013. Epub 2009 Apr 2.

PMID:
19345071
21.

Decline in the prevalence of pandemic clones Spain23F-1 and Spain9V-3 among US fluoroquinolone-resistant Streptococcus pneumoniae TRUST Surveillance isolates since 2001.

Davies TA, Yee YC, Goldschmidt R, Sahm DF, Evangelista AT.

Postgrad Med. 2008 Sep;120(3 Suppl 1):39-45. doi: 10.3810/pgm.2008.09.suppl52.283.

PMID:
18931470
22.
23.

Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae.

Davies TA, Yee YC, Bush K, Sahm D, Evangelista A, Goldschmidt R.

Microb Drug Resist. 2008 Sep;14(3):187-96. doi: 10.1089/mdr.2008.0805.

PMID:
18707553
24.

In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.

Amsler KM, Davies TA, Shang W, Jacobs MR, Bush K.

Antimicrob Agents Chemother. 2008 Sep;52(9):3418-23. doi: 10.1128/AAC.00336-08. Epub 2008 Jun 30.

25.

Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.

Davies TA, Shang W, Bush K, Flamm RK.

Antimicrob Agents Chemother. 2008 Apr;52(4):1510-2. doi: 10.1128/AAC.01529-07. Epub 2008 Feb 4.

26.

Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x.

Davies TA, Shang W, Bush K, Flamm RK.

J Antimicrob Chemother. 2008 Mar;61(3):751-3. doi: 10.1093/jac/dkn004. Epub 2008 Jan 31. No abstract available.

PMID:
18238882
27.

Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacin.

Davies TA, Leibovitz E, Noel GJ, McNeeley DF, Bush K, Dagan R.

Antimicrob Agents Chemother. 2008 Jan;52(1):378-81. Epub 2007 Nov 12.

28.

Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.

Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K.

Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4. Epub 2007 Apr 30.

30.

Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).

Davies TA, Yee YC, Goldschmidt R, Bush K, Sahm DF, Evangelista A.

J Antimicrob Chemother. 2006 Mar;57(3):437-42. Epub 2006 Jan 23.

PMID:
16431861
33.

Antimicrobial susceptibility and macrolide resistance inducibility of Streptococcus pneumoniae carrying erm(A), erm(B), or mef(A).

Syrogiannopoulos GA, Grivea IN, Ednie LM, Bozdogan B, Katopodis GD, Beratis NG, Davies TA, Appelbaum PC.

Antimicrob Agents Chemother. 2003 Aug;47(8):2699-702.

34.

Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000).

Davies TA, Goldschmidt R, Pfleger S, Loeloff M, Bush K, Sahm DF, Evangelista A.

J Antimicrob Chemother. 2003 Aug;52(2):168-75. Epub 2003 Jul 1.

PMID:
12837740
36.

Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.

Clark CL, Nagai K, Davies TA, Bozdogan B, Dewasse B, Jacobs MR, Appelbaum PC.

Clin Microbiol Infect. 2002 Jun;8(6):373-80.

38.

Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries.

Nagai K, Appelbaum PC, Davies TA, Kelly LM, Hoellman DB, Andrasevic AT, Drukalska L, Hryniewicz W, Jacobs MR, Kolman J, Miciuleviciene J, Pana M, Setchanova L, Thege MK, Hupkova H, Trupl J, Urbaskova P.

Antimicrob Agents Chemother. 2002 Feb;46(2):546-9.

39.

Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries.

Nagai K, Appelbaum PC, Davies TA, Kelly LM, Hoellman DB, Andrasevic AT, Drukalska L, Hryniewicz W, Jacobs MR, Kolman J, Miciuleviciene J, Pana M, Setchanova L, Thege MK, Hupkova H, Trupl J, Urbaskova P.

Antimicrob Agents Chemother. 2002 Feb;46(2):371-7.

40.

Antipneumococcal activity of BMS 284756 compared to those of six other agents.

Pankuch GA, Nagai K, Davies TA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2002 Jan;46(1):251-4.

41.

Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.

Canu A, Malbruny B, Coquemont M, Davies TA, Appelbaum PC, Leclercq R.

Antimicrob Agents Chemother. 2002 Jan;46(1):125-31.

42.
43.

Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.

Pankuch GA, Davies TA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2002 Jan;46(1):42-6.

44.

Evaluation of PCR primers to screen for Streptococcus pneumoniae isolates and beta-lactam resistance, and to detect common macrolide resistance determinants.

Nagai K, Shibasaki Y, Hasegawa K, Davies TA, Jacobs MR, Ubukata K, Appelbaum PC.

J Antimicrob Chemother. 2001 Dec;48(6):915-8.

PMID:
11733479
46.
47.

Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece.

Syrogiannopoulos GA, Grivea IN, Tait-Kamradt A, Katopodis GD, Beratis NG, Sutcliffe J, Appelbaum PC, Davies TA.

Antimicrob Agents Chemother. 2001 Jan;45(1):342-4.

48.

In vitro development of resistance to ceftriaxone, cefprozil and azithromycin in Streptococcus pneumoniae.

Nagai K, Davies TA, Dewasse BE, Pankuch GA, Jacobs MR, Appelbaum PC.

J Antimicrob Chemother. 2000 Dec;46(6):909-15.

PMID:
11102409
49.

Mediterranean clone of penicillin-susceptible, multidrug-resistant serotype 6B Streptococcus pneumoniae in Greece, Italy and Israel.

Syrogiannopoulos GA, Ronchetti F, Dagan R, Grivea I, Ronchetti MP, Porat N, Davies TA, Ronchetti R, Appelbaum PC, Jacobs MR.

Int J Antimicrob Agents. 2000 Nov;16(3):219-24.

PMID:
11091039
50.

Antimicrobial use and colonization with erythromycin-resistant Streptococcus pneumoniae in Greece during the first 2 years of life.

Syrogiannopoulos GA, Grivea IN, Davies TA, Katopodis GD, Appelbaum PC, Beratis NG.

Clin Infect Dis. 2000 Oct;31(4):887-93. Epub 2000 Oct 25.

PMID:
11049766

Supplemental Content

Loading ...
Support Center